TITLE

Value drivers in licensing deals

AUTHOR(S)
Arnold, Katie; Coia, Anthony; Saywell, Scott; Smith, Ty; Minick, Scott; Löffler, Alicia
PUB. DATE
November 2002
SOURCE
Nature Biotechnology;Nov2002, Vol. 20 Issue 11, p1085
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Determines the appropriate gauge on how the value of licensing deals in commercial biotechnology is identified, enhanced and captured. Three quantitative methods used to analyze biotechnology products; Value of product deals between biotechnology and pharmaceutical companies; Impact of the type of compound on the deal size; Greater value of global agreements.
ACCESSION #
7919124

 

Related Articles

  • OTHER NEWS TO NOTE.  // BioWorld Today;6/7/2010, Vol. 21 Issue 108, p6 

    This section offers news briefs concerning the biotechnology industries, which include the licensing agreement between Ascalon International Inc. and CerRx Inc., the agreement between Emisphere Technologies Inc. and Novartis AG and preclinical data on the dual agonist of Toll-like Receptor 7...

  • OTHER NEWS TO NOTE.  // BioWorld Today;2/2/2010, Vol. 21 Issue 21, p3 

    This section offers news briefs on the biotechnology industry including an exclusive worldwide licensing deal signed by Abbott with Pierre Fabre SA, the execution of a license agreement by Achillion Pharmaceuticals Inc. for elvucitabine, and the research agreements signed by Asuragen Inc. with...

  • Extracting Maximum Value from Your Patent Portfolio. Kaufman, Craig R. // BioPharm International;May2003, Vol. 16 Issue 5, p24 

    Discusses the importance of market surveillance and an effective litigation or licensing strategy for effective use of a patent portfolio in the biopharmaceutical industry. Prelitigation techniques; Infringement detection; Imposition of notice requirement on patent owners.

  • Increasing Complexity in Deals Can Be a Blessing or a Curse. Boggs, Jennifer // BioWorld Today;2/5/2008, Vol. 19 Issue 24, p1 

    The article discusses the highlights of the sixth annual Biopartnering North America conference held in Vancouver, British Columbia. Starting the first day of meetings, a group of biotech industry executives reviewed the shift from the traditional out-licensing deals in favor of those...

  • The Biotech Licensing Challenge. Lachman, Ranan // Drug Discovery & Development;Oct2004, Vol. 7 Issue 10, p13 

    Discusses the changes being faced by biotechnology licensing in the United States. Increasing role played by licensing in the business model of pharmaceutical and biotechnology companies; Conditions limiting successful execution of in-licensing strategy; Issues that biotechnology companies must...

  • COMPANY SPOTLIGHT - MedImmune, Inc.  // PharmaWatch: Biotechnology;Mar2005, Vol. 4 Issue 3, p21 

    The article features biotechnology company MedImmune, and offers information about its corporate history and financial performance. The firm is concentrating in the development and marketing of products in areas such as infectious disease, immune regulation and cancer. It has built a name in...

  • Are small biotechs still underselling themselves? Ransom, John // Nature Biotechnology;May2006, Vol. 24 Issue 5, p477 

    The article reports on the preparation of Alpharetta, Georgia-based small biotechnology firm AtheroGenics to complete phase 3 trial sites for its lead atherosclerosis compound, small molecule AGI-1067. If the outcome of the trial is successful, the 50-million-dollar licensing bet that...

  • OTHER NEWS TO NOTE.  // BioWorld Today;4/26/2007, Vol. 18 Issue 81, p2 

    The article presents news briefs on biotechnology industries. Celera awarded Laboratory Corp. of America a license to Celera's breast cancer metastasis and estrogen/progesterone receptor discoveries. IsoTis Inc. completed the transfer of rights for its PolyActive technology to OctoPlus NV....

  • OTHER NEWS TO NOTE.  // BioWorld Today;1/16/2008, Vol. 19 Issue 11, p7 

    This section offers news briefs related to the biopharmaceutics sector. ActivBiotics Inc. has extended the deadline by which interested parties can bid to purchase its assets. A subgrant award was received by Arteriocyte Inc. to further develop its technology. A license agreement was signed...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics